Add a Calcium Channel Blocker (CCB)
The next antihypertensive agent to add for this elderly male on Entresto (sacubitril-valsartan) and chlorthalidone 25mg is a dihydropyridine calcium channel blocker (CCB), such as amlodipine.
Rationale Based on Guidelines
This recommendation follows the standard three-drug combination strategy endorsed by multiple international hypertension guidelines. The patient currently has:
- RAS blocker (valsartan component of Entresto)
- Thiazide-like diuretic (chlorthalidone)
The logical third agent is a dihydropyridine CCB to complete the preferred triple-therapy combination 1, 2.
The 2020 ISH Global Hypertension Guidelines explicitly recommend that when BP is not controlled with a two-drug combination, the next step is to increase to a three-drug combination, "usually a RAS blocker with a dihydropyridine CCB and a thiazide/thiazide-like diuretic" 1. The 2024 ESC Guidelines similarly state that if BP is not controlled with two drugs, "increasing to a three-drug combination is recommended, usually a RAS blocker with a dihydropyridine CCB and a thiazide/thiazide-like diuretic" 2.
Multiple guideline sources from 2014-2020 consistently identify the CCB + thiazide + ACEI/ARB combination as the preferred three-drug regimen 3, 1.
Special Considerations for Elderly Patients
Monitoring Requirements
In elderly patients, particularly those on Entresto, careful monitoring is essential 4:
- Blood pressure monitoring - including orthostatic measurements, as elderly patients have increased risk of symptomatic hypotension
- Renal function and serum potassium - monitor closely given the combination of RAS blockade and diuretic therapy
- Frailty assessment - individualize BP targets based on frailty status 1, 2
Dosing Strategy
- Start with low-dose CCB (e.g., amlodipine 2.5-5mg daily) given the elderly patient population
- Initial doses should be more gradual in elderly patients due to greater chance of adverse effects 5
- Titrate slowly based on response and tolerability
Blood Pressure Targets
The 2020 ISH Guidelines recommend targeting BP <140/90 mmHg in elderly patients, with individualization based on frailty 1. The 2024 ESC Guidelines suggest targeting systolic BP 120-129 mmHg if well tolerated, but emphasize the "as low as reasonably achievable" (ALARA) principle when treatment is poorly tolerated 2.
Common Pitfalls to Avoid
Do NOT add a beta-blocker as the third agent unless there is a compelling indication (e.g., angina, post-MI, heart failure with reduced ejection fraction, or rate control) 2
Do NOT add another RAS blocker - combining ACE inhibitors with ARBs is contraindicated and increases risk of hyperkalemia, hypotension, and renal dysfunction 6, 7, 2, 8
Avoid non-dihydropyridine CCBs (diltiazem, verapamil) if the patient is on or may need a beta-blocker, as this combination increases risk of heart block 6
Monitor for hypotension - Entresto already carries risk of symptomatic hypotension 8, and adding a CCB will further lower BP. The 2022 ESC Working Group specifically notes that sacubitril-valsartan causes "more symptomatic hypotension" and requires BP monitoring 4
Check adherence first - before adding another medication, verify the patient is actually taking the current regimen consistently 1
Alternative Considerations
If a CCB is contraindicated or not tolerated, the fourth-line agent would typically be spironolactone (or if contraindicated: amiloride, doxazosin, eplerenone, clonidine, or beta-blocker) 1. However, this is generally reserved for resistant hypertension after optimizing the three-drug combination.
Given that chlorthalidone is already at 25mg daily (a standard dose), and assuming Entresto is at an appropriate dose, adding a CCB represents the evidence-based next step before considering resistant hypertension workup or referral to a hypertension specialist 1.